Disposition of 831 shares by Moshe Giladi of Novocure at 107.73 subject to Rule 16b-3
| NVCR Stock | USD 17.09 0.23 1.36% |
Slightly above 52% of Novocure's retail investors are presently thinking to get in. The analysis of overall sentiment of trading Novocure stock suggests that some investors are interested at this time. Novocure's investing sentiment overview a quick insight into current market opportunities from investing in Novocure. Many technical investors use Novocure stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Novocure |
Filed transaction by Novocure Officer: Chief Science Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Novocure Fundamental Analysis
We analyze Novocure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novocure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novocure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Novocure is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Novocure Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Novocure stock to make a market-neutral strategy. Peer analysis of Novocure could also be used in its relative valuation, which is a method of valuing Novocure by comparing valuation metrics with similar companies.
Peers
Novocure Related Equities
| LIVN | LivaNova PLC | 3.30 | ||||
| TMDX | TransMedics | 2.77 | ||||
| MASI | Masimo | 2.53 | ||||
| ITGR | Integer Holdings | 1.88 | ||||
| GMED | Globus Medical | 1.58 | ||||
| NARI | Inari Medical | 1.53 | ||||
| CNMD | CONMED | 1.44 | ||||
| INMD | InMode | 1.37 | ||||
| INSP | Inspire Medical | 0.77 | ||||
| PEN | Penumbra | 0.54 | ||||
| IRTC | IRhythm Technologies | 0.22 | ||||
| PODD | Insulet | 1.72 |
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.